Literature DB >> 25604575

Catastrophic APS in the context of other thrombotic microangiopathies.

Ignasi Rodríguez-Pintó1, Gerard Espinosa, Ricard Cervera.   

Abstract

The catastrophic antiphospholipid syndrome (CAPS) is a rare disease that affects 1 % of cases with antiphospholipid syndrome (APS). CAPS can mimic or overlap with different thrombotic diseases; many patients present with a microthrombotic storm or thrombotic microangiopathic hemolytic anemia (TMHA). Thus, the differential diagnosis of CAPS includes thrombotic thrombocytopenic purpura (TTP), typical and atypical hemolytic uremic syndrome (HUS), systemic infections, malignancies, pregnancy-related disorders, malignant hypertension, heparin-induced thrombocytopenia, and drug-induced thrombotic microangiopathies. Antiphospholipid antibody (aPL) positivity has been proposed as the clue in this differential diagnosis; however, aPL can also occur in healthy people and in those with infections or malignancies. Thus, the differential diagnosis of an aPL-positive patient presenting with a microthrombotic storm is broad; the workup should include a special attention to signs of infection and disseminated malignant disease, assessing the funduscopic signs of malignant hypertension, testing ADAMTS13 activity and anti-heparin-platelet factor 4 (HPF4) antibodies, and searching previous exposure to certain drugs. This article aims to review the main diseases included in the differential diagnosis of CAPS in the context of other thrombotic microangiopathies.

Entities:  

Mesh:

Year:  2015        PMID: 25604575     DOI: 10.1007/s11926-014-0482-z

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  101 in total

1.  Occurrence of thrombotic thrombocytopenic purpura in a systemic lupus erythematosus patient with antiphospholipid antibodies in association with a decreased activity of von Willebrand factor-cleaving protease.

Authors:  J Matsuda; T Sanaka; K Gohchi; K Matsui; S Uchida; M Matsumoto; Y Fujimura
Journal:  Lupus       Date:  2002       Impact factor: 2.911

2.  [Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia].

Authors:  C GASSER; E GAUTIER; A STECK; R E SIEBENMANN; R OECHSLIN
Journal:  Schweiz Med Wochenschr       Date:  1955-09-20

3.  Transfusion medicine illustrated: An imPRESsive mimic.

Authors:  Laura Cooling; Steven Gay; Samuel Silver
Journal:  Transfusion       Date:  2010-01       Impact factor: 3.157

Review 4.  Clinical practice. Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally; Thomas L Ortel
Journal:  N Engl J Med       Date:  2006-08-24       Impact factor: 91.245

Review 5.  Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases.

Authors:  José A Gómez-Puerta; Ricard Cervera; Gerard Espinosa; Ronald A Asherson; Mario García-Carrasco; Izaias P da Costa; Danieli C O Andrade; Eduardo F Borba; Alexander Makatsaria; Silvia Bucciarelli; Manuel Ramos-Casals; Josep Font
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

6.  Acute fatty liver and HELLP syndrome: two distinct pregnancy disorders.

Authors:  P Vigil-De Gracia
Journal:  Int J Gynaecol Obstet       Date:  2001-06       Impact factor: 3.561

Review 7.  The catastrophic antiphospholipid (Asherson's) syndrome and malignancies.

Authors:  W Miesbach; R A Asherson; R Cervera; Y Shoenfeld; J Gomez Puerta; S Bucciarelli; G Espinoza; J Font
Journal:  Autoimmun Rev       Date:  2006-07-21       Impact factor: 9.754

Review 8.  Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia.

Authors:  Steven E McKenzie; Bruce S Sachais
Journal:  Curr Opin Hematol       Date:  2014-09       Impact factor: 3.284

Review 9.  Catastrophic antiphospholipid syndrome: diagnosis and management in pregnancy.

Authors:  Jose A Gómez-Puerta; Gerard Espinosa; Ricard Cervera
Journal:  Clin Lab Med       Date:  2013-04-19       Impact factor: 1.935

10.  Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura.

Authors:  Valentina Bianchi; Rodolfo Robles; Lorenzo Alberio; Miha Furlan; Bernhard Lämmle
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

View more
  12 in total

Review 1.  Treatment of catastrophic antiphospholipid syndrome.

Authors:  Nayef M Kazzaz; W Joseph McCune; Jason S Knight
Journal:  Curr Opin Rheumatol       Date:  2016-05       Impact factor: 5.006

2.  Complement Activation and Thrombotic Microangiopathies.

Authors:  Marta Palomo; Miquel Blasco; Patricia Molina; Miquel Lozano; Manuel Praga; Sergi Torramade-Moix; Julia Martinez-Sanchez; Joan Cid; Gines Escolar; Enric Carreras; Cristina Paules; Fatima Crispi; Luis F Quintana; Esteban Poch; Lida Rodas; Emma Goma; Johann Morelle; Mario Espinosa; Enrique Morales; Ana Avila; Virginia Cabello; Gema Ariceta; Sara Chocron; Joaquin Manrique; Xoana Barros; Nadia Martin; Ana Huerta; Gloria M Fraga-Rodriguez; Mercedes Cao; Marisa Martin; Ana Maria Romera; Francesc Moreso; Anna Manonelles; Eduard Gratacos; Arturo Pereira; Josep M Campistol; Maribel Diaz-Ricart
Journal:  Clin J Am Soc Nephrol       Date:  2019-11-06       Impact factor: 8.237

3.  A 37-Year-Old Man With Primary Antiphospholipid Syndrome Presenting With Respiratory Distress and Worsening Toe Ischemia.

Authors:  Nayef M Kazzaz; Allecia M Wilson; Ruba Kado; Geoffrey D Barnes; Jason S Knight
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-08       Impact factor: 4.794

Review 4.  Probable Catastrophic Antiphospholipid Syndrome with Intracerebral Hemorrhage Secondary to Epstein-Barr Viral Infection.

Authors:  Mark P Plummer; Adam M H Young; Ronan O'Leary; Maxwell S Damian; Andrea Lavinio
Journal:  Neurocrit Care       Date:  2018-02       Impact factor: 3.210

Review 5.  Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.

Authors:  Maria Izabel de Holanda; Luis Cristóvão Pôrto; Teresa Wagner; Luis Fernando Christiani; Lilian M P Palma
Journal:  Clin Rheumatol       Date:  2017-09-13       Impact factor: 2.980

Review 6.  HUS and atypical HUS.

Authors:  T Sakari Jokiranta
Journal:  Blood       Date:  2017-04-17       Impact factor: 25.476

Review 7.  Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome.

Authors:  Andrew P Vreede; Paula L Bockenstedt; W Joseph McCune; Jason S Knight
Journal:  Curr Opin Rheumatol       Date:  2019-05       Impact factor: 5.006

8.  HEMOLYTIC UREMIC SYNDROME ASSOCIATED WITH STREPTOCOCCUS PNEUMONIAE IN PEDIATRICS: A CASE SERIES.

Authors:  Oscar Javier León Guerra; Ricardo Saul Galeano Rodríguez; William Javier Morales Camacho; Jessica Estefanía Plata Ortiz; María Alejandra Morales Camacho
Journal:  Rev Paul Pediatr       Date:  2019-11-25

9.  The pathogenesis of thromboembolic disease in covid-19 patients: Could be a catastrophic antiphospholipid syndrome?

Authors:  Giulia Previtali; Michela Seghezzi; Valentina Moioli; Aurelio Sonzogni; Lorenzo Cerutti; Roberto Marozzi; Rudi Ravasio; Andrea Gianatti; Giovanni Guerra; Maria Grazia Alessio
Journal:  Thromb Res       Date:  2020-06-27       Impact factor: 3.944

10.  Eculizumab in a pregnant patient with laboratory onset of catastrophic antiphospholipid syndrome: A case report.

Authors:  Patrizia Rovere-Querini; Valentina Canti; Roberta Erra; Esperia Bianchi; Giorgio Slaviero; Armando D'Angelo; Susanna Rosa; Massimo Candiani; Maria Teresa Castiglioni
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.